Effect of Vitamin K2 (MK7) on Cardiovascular and Bone Disease in Dialysis Patients

2016-11-30 15:45:34 | BioPortfolio


Cardiovascular disease (CVD) is the most frequent cause of death in patients (ptt.) with chronic kidney disease (CKD). Compared to the general population death due to CVD is 10-20 times higher in CKD ptt. being treated with hemodialysis. Vascular calcification and hence arterial stiffness is of great importance for the high incidence of CVD.

CKD ptt. in dialysis treatment also have a 3 times higher risk of bone fractures. Both vertebral and other fractures of low energy are associated with a high mortality.

Matrix Gla Protein (MGP) is an important inhibitor of vascular calcification and Osteocalcin (OC) is an important regulator of bone metabolism. The function of both MGP and OC depend on vitamin K.

Vitamin K is supplied with food. The content is low in food recommended to CKD ptt. which is reflected in very low concentrations of vitamin K in their blood samples. A correlation between vitamin K level, incidence of vascular calcification and bone density has been proven; yet there are no trials elucidating the clinical effect of vitamin K on vascular calcification or bone strength.

The investigators will conduct a randomized placebo controlled trial examining the clinical effects of vitamin K2 on vascular calcification and bone mineralization in order to prevent and treat CVD and bone disease in CKD ptt.

Primary study endpoints:

1. Changes in arterial stiffness assessed by pulse wave examination

2. Changes in bone mineral density (BMD) in distal radius assessed by DXA-scans.

Secondary study endpoints:

Changes in coronary artery and valvular calcification assessed by heart-CT-scans, blood pressure, body composition, total and regional BMD, lateral column/aortic calcification score as well as a panel of correlating blood tests.



Vascular calcification is a significant problem among patients (ptt.) with chronic kidney disease (CKD) and the prevalence of aortic calcification is twice as high as the general population e.g. Cardiovascular disease (CVD) is the most frequent cause of death in ptt. with CKD. Death due to CVD is 10-20 times higher in CKD ptt. being treated with hemodialysis compared to the background population. Whereas atherosclerosis is a dominating cause of CVD in the general population CKD ptt. tend to develop medial calcification and hence arterial stiffness which is thought to be of great importance in the high incidence of CVD.

CKD ptt. in dialysis treatment also have a 3 times higher risk of bone fractures compared to the general population. Both vertebral and other fractures of low energy are associated with a high mortality in CKD ptt.

The genesis of the arteriosclerosis is still unresolved but seems to be multifactorial. The impaired kidney function itself and the treatment so far both seem to be of importance. The vitamin K-dependent Gla proteins; Matrix Gla Protein (MGP) and Osteocalcin (OC) are described as the most potent inhibitors of vascular calcification and osteoporosis. Until recently CKD ptt. have been treated with vitamin K antagonists which just adds to the focus on vitamin K in this progressive, vascular calcification- and bone demineralization process.

Vitamin K is supplied with food. It consists of several subtypes, e.g. vitamin K1 which is transformed into K2 during digestion. The recommended diet for CKD ptt. is low on vitamin K which is reflected in very low concentrations of vitamin K in blood samples from CKD ptt. in hemodialysis. A supplement of vitamin K1 or K2 will make activation possible for MGP and OC by increasing the concentration of vitamin K2.

A correlation between vitamin K level and incidence of vascular calcification in dialysis ptt. has been proven; yet there are no trials elucidating the clinical effect of vitamin K on vascular calcification in CKD ptt. There are not any trials elucidating the effect of vitamin K on bone strength or number of fractures in dialysis ptt, although a relation between vitamin K and bone mineral density in dialysis ptt. has been shown and a significant increase in age related bone strength was found in a study by introducing a daily supplement of vitamin K.


To examine the clinical effect of vitamin K2(MK7) on arterial stiffness assessed by pulse wave examination and bone mineral density assessed by DXA-scans in a group of dialysis ptt. in order to be able to prevent and treat cardiovascular and bone disease in CKD ptt. in the future.

The hypothesis is that a daily supplement of vitamin K2 (MK7) will reduce the calcification process in larger arteries, coronary arteries and -valves and hence reduce the risk of CVD as well as increase the bone mineral density and hence the frequency of bone fractures.


RenaKvit is an investigator initiated, prospective, randomized, double-blinded, placebo controlled intervention trial performed as a nationally, multicenter trial that will run for 2 years. Data will be compiled after 1 and 2 years.

The trial is divided into two sub-studies; RenaKvit-kar (vessel) and RenaKvit-knogle (bone), in which the effect of vitamin K2(MK7) on larger arteries, coronary arteries- and valves and the effect on bone with regards to bone mineral density and frequency of fractures are respectively examined.


Ptt. will be equally divided by randomization and hence daily be given a tablet of either vitamin K2(MK7) or placebo. According to the criteria of inclusion ptt. will either join the RenaKvit-vessel or the bone group. If criteria are fulfilled ptt. are to join both vessel and bone groups.

Determined by calculation of statistical power, incl. a level of significance of 5%, a standard deviation of 0,95 and strength of 80%, a minimum of 40 + 140 ptt. will be included, thus taking potentially drop-outs in account. Both ptt. in hemo- and peritoneal dialysis treatment will be included.

Ptt. will be recruited by the dialysis departments at Roskilde, Nykoebing falster, Holbaek and Slagelse Hospitals.

There will be no fee for participating ptt.


Patients are given either vitamin K 360 micrograms or placebo once daily during a period of 2 x 12 months. Both types of tablets will be of similar look and content, besides vitamin K2.


- Pulse Wave examination: Includes both pulse wave analysis and pulse wave velocity measurements. Done by using SphygmoCor©-pulse wave apparatus. Pulse wave examination is used as a measure of the arterial stiffness and is performed after standardized method.

- 24-hour blood pressure and blood pressure measurements: Done by current Danish guidelines (17).

- Coronary artery and -valve calcification: Assessed by CT-scans of the heart using the Agatston Score.

- Bone Mineral Density: Assessed by DEXA-scans.

- Lateral lumbal x- ray and aortic calcification score: A semi-quantitative scoring system used to describe the plaques on the front and the back of the aorta level with each level of the lumbar vertebrae. The method has been found to be predictive of vascular morbidity and mortality.

- Measuring predictors/establishing a biobank: Partly as "routine tests" during dialysis and partly as special kits developed at Vejle Hospital.


Both groups will have descriptive statistics performed for as well as the presentation of the total population, stratified for gender, age and weight.

Normal-distributed data will be expressed as mean value +/- standard deviation (SD), while other distributed data also will be expressed as median values (interquartile range; interquartile range, IQR). Categorical values will be expressed in numbers and percentages.

Normal-distributed variables will be compared with Student's t-test. Where found appropriate, logarithmic transformation shall be performed. Non-normally distributed variables will be compared with the Mann Whitney U test. Categorical values are to be compared with the Chi Square test.

Changes in the two groups over time will be analyzed by paired analysis, and the two groups compared with the non-paired analysis. Forward stepwise multivariate logistic regression analysis is carried out to correct significant confounders of the primary and secondary endpoints.

Analysis of Cox proportional hazards will be performed from time to first clinical event.

P≤0.05 will be considered statistically significant. All results - negative and positive - are expected to be published in peer-review magazines.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Vitamin K Supplementation


Vitamin K2 (MK7), Placebo


Holbaek Hospital




Zealand University Hospital

Results (where available)

View Results


Published on BioPortfolio: 2016-11-30T15:45:34-0500

Clinical Trials [1713 Associated Clinical Trials listed on BioPortfolio]

Vitamin B12 Supplementation Study

We hope to learn the clinical and functional signs of sub-clinical vitamin B12 deficiency and its response to supplementation in non-anemic, non-pregnant, and non-lactating women in Rural ...

Optimizing Vitamin D Nutrition in Healthy Adults

The purpose of this study is to determine the average dosage of oral vitamin D supplementation to maintain optimal vitamin D levels in the body and to see if there are differences in the r...

Vitamin D Supplementation and Neurocognition

This study will evaluate the effect of vitamin D supplementation on the neurocognitive function of older people with lower than normal levels of vitamin D at baseline

Vitamin D Supplementation in Wheelchair Indoor Athletes

There is a high prevalence of vitamin D deficiency in Switzerland. In indoor-athletes as well as wheelchair users, vitamin D deficiency occurs even more often. It is well established that ...

Comparison of 25-hydroxy Vitamin D Level in Caucasian Women Receiving Vitamin D Supplementation and Not Receiving Supplementation: a Randomized Controlled Trial.

The objective of this study is to assess whether vitamin D supplements are sufficient to increase females who are deficient or borderline deficient in vitamin D levels to normal levels.

PubMed Articles [2675 Associated PubMed Articles listed on BioPortfolio]

Clinical and Metabolic Response to Vitamin D Supplementation in Endometrial Hyperplasia: a Randomized, Double-Blind, Placebo-Controlled Trial.

There was inconsistent evidence showing that vitamin D intake may be associated with reduced cancer risk due to optimized metabolic profile and reduced oxidative stress. However, we are not aware of a...

Circulating 25-Hydroxy Vitamin D Relative to Vitamin D Receptor Polymorphism after Vitamin D3 Supplementation in Breast Cancer Women: A Randomized, Double-Blind Controlled Clinical Trial

Objective: The influence of vitamin D receptor (VDR) genetic variation on serum 25-hydroxyvitamin D levels [25(OH)D] after vitamin D3 supplementation remains unclear. We aimed to investigate changes o...

Cholecalciferol supplementation of heifer diets increases beef vitamin D concentration and improves beef tenderness.

This study investigated the effects of cholecalciferol (vitamin D₃) supplementation on beef vitamin D activity, beef tenderness and sensory attributes. Thirty heifers were randomly allocated to one ...

Multi-dose vitamin d supplementation in stable very preterm infants: Prospective randomized trial response to three different vitamin D supplementation doses.

Preterm newborns are born with lower vitamin D stores. Although vitamin D supplementation is recommended there is no consensus regarding the adequate dose of supplementation for preterm infants.

Maternal Preferences for Vitamin D Supplementation in Breastfed Infants.

Daily vitamin D supplementation is recommended for breastfed infants, but alternative methods include enriching breast milk with vitamin D through maternal supplementation or intermittent high-dose vi...

Medical and Biotech [MESH] Definitions

A lipid cofactor that is required for normal blood clotting. Several forms of vitamin K have been identified: VITAMIN K 1 (phytomenadione) derived from plants, VITAMIN K 2 (menaquinone) from bacteria, and synthetic naphthoquinone provitamins, VITAMIN K 3 (menadione). Vitamin K 3 provitamins, after being alkylated in vivo, exhibit the antifibrinolytic activity of vitamin K. Green leafy vegetables, liver, cheese, butter, and egg yolk are good sources of vitamin K.

A nutritional condition produced by a deficiency of VITAMIN D in the diet, insufficient production of vitamin D in the skin, inadequate absorption of vitamin D from the diet, or abnormal conversion of vitamin D to its bioactive metabolites. It is manifested clinically as RICKETS in children and OSTEOMALACIA in adults. (From Cecil Textbook of Medicine, 19th ed, p1406)

OXIDOREDUCTASES which mediate vitamin K metabolism by converting inactive vitamin K 2,3-epoxide to active vitamin K.

A family of phylloquinones that contains a ring of 2-methyl-1,4-naphthoquinone and an isoprenoid side chain. Members of this group of vitamin K 1 have only one double bond on the proximal isoprene unit. Rich sources of vitamin K 1 include green plants, algae, and photosynthetic bacteria. Vitamin K1 has antihemorrhagic and prothrombogenic activity.

A nutritional condition produced by a deficiency of VITAMIN E in the diet, characterized by posterior column and spinocerebellar tract abnormalities, areflexia, ophthalmoplegia, and disturbances of gait, proprioception, and vibration. In premature infants vitamin E deficiency is associated with hemolytic anemia, thrombocytosis, edema, intraventricular hemorrhage, and increasing risk of retrolental fibroplasia and bronchopulmonary dysplasia. An apparent inborn error of vitamin E metabolism, named familial isolated vitamin E deficiency, has recently been identified. (Cecil Textbook of Medicine, 19th ed, p1181)

More From BioPortfolio on "Effect of Vitamin K2 (MK7) on Cardiovascular and Bone Disease in Dialysis Patients"

Quick Search

Searches Linking to this Trial